TY - JOUR
T1 - The Path to Group A Streptococcus Vaccines
T2 - World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
AU - Vekemans, Johan
AU - Gouvea-Reis, Fernando
AU - Kim, Jerome H.
AU - Excler, Jean Louis
AU - Smeesters, Pierre R.
AU - O'brien, Katherine L.
AU - Van Beneden, Chris A.
AU - Steer, Andrew C.
AU - Carapetis, Jonathan R.
AU - Kaslow, David C.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.
AB - Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.
KW - group A Streptococcus
KW - pharyngitis
KW - rheumatic heart disease
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85065536515&partnerID=8YFLogxK
U2 - 10.1093/cid/ciy1143
DO - 10.1093/cid/ciy1143
M3 - Review article
C2 - 30624673
AN - SCOPUS:85065536515
SN - 1058-4838
VL - 69
SP - 877
EP - 883
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
M1 - ciy1143
ER -
